• Wondering whether Ventas at around US$84.42 is offering fair value or if you might be overpaying for future growth? This article explains what the current price could be indicating about the stock.
• The stock is up 9.2% year to date and 34.9% over the past year, even though it has slipped 4.3% over the last week and 3.4% over the past month. Over 3 years it is up 105.4% and over 5 years it has gained 76.2%.
• Recent coverage around Ventas has focused on its position in the Health Care REITs space and broader interest in income focused real estate investments. Combined with its recent share price moves, this has kept attention on whether the current valuation still makes sense for new and existing shareholders.
• Right now Ventas holds a value score of 3/6. This suggests some checks point to potential undervaluation while others do not. The rest of this article will look at standard valuation methods and then finish with a more holistic way to think about what the stock might be worth.

Approach 1: Ventas Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting its future adjusted funds from operations and discounting those cash flows back to today in dollar terms.

For Ventas, the latest twelve month free cash flow is about $1.62b. Analysts provide free cash flow estimates for several years, and these are then extended further using the same 2 stage Free Cash Flow to Equity approach based on adjusted funds from operations. On this basis, projected free cash flow for 2030 is $2.35b, with intermediate years between 2026 and 2035 ranging from about $1.55b to $3.06b in nominal terms, before discounting.

When all those future cash flows are discounted back to today, the model arrives at an estimated intrinsic value of $110.94 per share. Compared with the current share price of about $84.42, this implies Ventas is trading at a 23.9% discount to this DCF estimate, which indicates the stock is undervalued according to this method.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Ventas is undervalued by 23.9%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Ventas Price vs Sales

For profitable companies, price-based multiples are a straightforward way to see what investors are paying for each unit of business performance. For Ventas, the preferred measure is the Price to Sales, or P/S, ratio, which compares the stock price to the revenue the company generates.

Expectations for future growth and the risk around those expectations usually drive what looks like a normal or fair multiple. Higher expected growth or lower perceived risk can justify a higher P/S ratio, while slower growth or higher risk usually point to a lower multiple.

Ventas currently trades on a P/S of 6.71x, compared with the Health Care REITs industry average of 6.70x and a peer group average of 7.41x. Simply Wall St also calculates a proprietary Fair Ratio of 5.63x for Ventas. This Fair Ratio is designed to be more tailored than a simple peer or industry comparison because it folds in factors such as earnings growth, profit margins, risk profile, industry and overall market cap.

Comparing the Fair Ratio of 5.63x with the current P/S of 6.71x suggests the stock is trading above that tailored fair estimate.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Ventas Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story for Ventas to the numbers by linking your view on its future revenue, earnings and margins to a forecast. This turns that into a fair value you can compare with the current price, updating automatically when news or earnings arrive. It also allows very different perspectives. For example, one investor might align with the higher analyst fair value of about $110.00, while another might lean toward the lower end near $86.00. All of this is available within an easy to use tool on the Community page that helps you decide whether the price looks rich or reasonable against your own assumptions.

Do you think there's more to the story for Ventas? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.